Pay in 4 interest-free payments of $5.39 Learn more
Ships within 48 hours · Estimated delivery Oct 29 - Nov 3
A significant discovery is that liraglutide, a GLP-1RA, inhibits the activation of Notch1
An initial analysis of the FDA adverse event reporting system (FAERS) data demonstrated no consistent trends in DKA with SGLT2i use over time [39], however an alternative cohort study of 50,220 individuals with type 2 diabetes showed the highest risk of DKA shortly after SGLT2i initiation, which subsequently reduced with time [40]
o Vomiting: Can occur in some patients, particularly if the nausea is severe
Kosiborod MN, Petrie MC, Borlaug BA, Butler J, Davies MJ, Hovingh GK, Kitzman DW, Moller DV, Treppendahl MB, Verma S, et al
Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the carolina randomized clinical trial
